Tocilizumab in rheumatoid arthritis;Tocilizumab en artritis reumatoide

Reumatologia Clinica

Volumn 6, Issue SUPPL. 3, 2010, Pages

  Rueda Gotor, Javier ^a   Blanco Alonso, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Monotherapy; Rheumatoid arthritis; Tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ACUTE PHASE RESPONSE; ANEMIA; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; INFLAMMATORY DISEASE; MONOTHERAPY; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DISEASE PREDISPOSITION; DRUG COMBINATION; DRUG-INDUCED LIVER INJURY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; INFECTION; MULTICENTER STUDY (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DISEASE SUSCEPTIBILITY; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; HUMANS; HYPERCHOLESTEROLEMIA; INFECTION; METHOTREXATE; MULTICENTER STUDIES AS TOPIC; RECEPTORS, INTERLEUKIN-6;

EID: 79952899921     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.01.001     Document Type: Article

References (15)

1. Pablos Álvarez J.L. La interleucina 6 en la fisiopatología de la artrirtis reumatoide. Reumatol Clin. 2009, 5. 34-9.05.
2. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Broll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006, 54:2817-2829. CHARISMA Study Group.
3. Nishimoto N., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Azuma J., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009, 19:12-19.
4. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI). Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007, 66:1162-1167.
5. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008, 371:989-997.
6. Kremer J.M., Fleischmann R.M., Halland A.M., Brzezicki J., Woodworth T., Fisheleva E., et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE study. Arthritis Rheum. 2008, 589(Suppl2):L11.
7. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., Da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therpy study. Arthritis Rheum. 2008, 58:2968-2980.
8. Emery P., Keystone E., Tony H.P., Cantagrel A., Van Vollenhoven R., Sánchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008, 67:516-523.
9. Jones G., Sebba A., Gu J., Lowenstein M., Calvo A., Gomez-Reino J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010, 69:88-96.
10. Rubbert-Roth A., Braun J., Feist E., Kellner H., Burmester G. Interim Results of the TAMARA Study Effectiveness and Safety of the Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab After 4 and 24 Weeks in Patients with Active Rheumatoid Arthritis (RA) [abstract]. Arthritis Rheum. 2009, 60(Suppl 10):412.
11. Bykerk V., Östör A., Álvaro-Gracia J., Pavelka K., Bernasconi C., Stancati A., et al. Tocilizumab in patients with rheumatoid arthritis and an inadequate response to dmards and/or tnf inhibitor therapy: ACT-SURE preliminary results. Ann Rheum Dis. 2010, 69(Suppl 3):379.
12. Smolen J., Gomez-Reino J.J., Vernon E., Rubbert-Roth A., Emery P. Efficacy of tocilizumab in patients with ra and inadequate response to DMARDs or TNF inhibitors: up to 3.5-year data from ongoing extension studies. Ann Rheum Dis. 2010, 69(Suppl 3):386.
13. Jones G., Sebba A., Calvo A., Tate G., Beaulieu A., Vernon E., et al. Efficacy of Tocilizumab in patients with rheumatoid arthritis who had never been exposed to or had never failed methotrexate: analysis of up to 3 years of treatment in a long-term extension study. Ann Rheum Dis. 2010, 69(Suppl 3):386.
14. Smolen J.S., Beaulieu A.D., Dikranian A., Fenton I., Fisheleva E., Alecock E., et al. Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials. Arthritis Rheum. 2008, 589 Suppl:1669.
15. Van Vollenhoven R.F., Scali J., Curtis J.R., Krasnow J., Vernon E., Alten R., et al. Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 2.6 years of treatment in long-term extension studies. Ann Rheum Dis. 2010, 69(Suppl3):544.